ProCE Banner Activity

TROP-2–Targeting Antibody–Drug Conjugates: Perspectives for the Oncology Nurse Specialist

Clinical Thought

Read this commentary by an oncology nurse practitioner for a review of TROP-2–targeting ADC therapy, including a list of current FDA approvals, an update of the phase III TROPiCS-02 trial from ASCO 2023, and a summary of adverse events associated with these agents.

Released: July 26, 2023

Share

Faculty

Srigowri Kota

Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN

Nurse Practitioner
Department of Genitourinary Medical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc. 

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN

Nurse Practitioner
Department of Genitourinary Medical Oncology
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey

Srigowri Kota, MSN, BA, APRN, AGNP-C, OCN, has no relevant financial relationships to disclose.